Teva Pharmaceutical (TEVA) director reports 50,000-share sale

Rhea-AI Filing Summary

Teva Pharmaceutical Industries Ltd. director reports share sale. A reporting person serving as a director of Teva Pharmaceutical Industries Ltd. (TEVA) sold 50,000 Ordinary Shares on 11/26/2025 in an open-market transaction coded "S" for sale. The shares were sold at a weighted average price of $26.0301 per share, with individual trades ranging from $26.03 to $26.035.

After this transaction, the reporting person is shown as beneficially owning 445,000 Ordinary Shares indirectly through Swiftcurrent Master Fund Ltd. and 105,315 Ordinary Shares directly. The filing notes that the Ordinary Shares may be represented by American Depositary Shares, each currently representing one Ordinary Share, and that certain indirect holdings are disclaimed except for any indirect pecuniary interest.

Insider Trade Summary

Net Seller: 50,000 shares ($1,301,505)

Net Sell 2 txns

Insider MIGNONE ROBERTO

Role Director

Sold 50,000 shs ($1.30M)

Type	Security	Shares	Price	Value
Sale	Ordinary Shares	50,000	$26.0301	$1.30M
holding	Ordinary Shares	--	--	--

Holdings After Transaction: Ordinary Shares — 445,000 shares (Indirect, [see footnote]); Ordinary Shares — 105,315 shares (Direct)

Footnotes (1)

1. The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.03 to $26.035, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price. The 445,000 Ordinary Shares disclosed in Table I of this Form 4 are held of record by Swiftcurrent Master Fund Ltd. (the "Fund"). Bridger Management, LLC is the investment adviser to the Fund and Mr. Mignone is the manager of Bridger Management, LLC. By reason of the provisions of Rule 16a-1(a)(1) under the Securities Exchange Act of 1934, as amended, Mr. Mignone may be deemed to beneficially own the Ordinary Shares held of record by the Fund. Mr. Mignone disclaims beneficial ownership of the Ordinary Shares held of record by the Fund except to the extent of his indirect pecuniary interest therein and this report shall not be deemed an admission that Mr. Mignone is the beneficial owner of the Ordinary Shares held of record by the Fund for purposes of Section 16, or for any other purpose.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

MIGNONE ROBERTO

(Last) (First) (Middle)

C/O TEVA PHARMACEUTICAL INDUSTRIES LTD.

124 DVORA HANEVI'A ST.,

(Street)

TEL AVIV L3 6944020

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
TEVA PHARMACEUTICAL INDUSTRIES LTD [ TEVA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
11/26/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Ordinary Shares(1)	11/26/2025		S		50,000	D	$26.0301(2)	445,000	I	[see footnote](3)
Ordinary Shares(1)								105,315	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.03 to $26.035, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price.

3. The 445,000 Ordinary Shares disclosed in Table I of this Form 4 are held of record by Swiftcurrent Master Fund Ltd. (the "Fund"). Bridger Management, LLC is the investment adviser to the Fund and Mr. Mignone is the manager of Bridger Management, LLC. By reason of the provisions of Rule 16a-1(a)(1) under the Securities Exchange Act of 1934, as amended, Mr. Mignone may be deemed to beneficially own the Ordinary Shares held of record by the Fund. Mr. Mignone disclaims beneficial ownership of the Ordinary Shares held of record by the Fund except to the extent of his indirect pecuniary interest therein and this report shall not be deemed an admission that Mr. Mignone is the beneficial owner of the Ordinary Shares held of record by the Fund for purposes of Section 16, or for any other purpose.

	/s/ Dov Bergwerk as attorney-in-fact for Roberto Mignone	12/01/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.